Malignant hyperthermia: Pharmacology of triggering

British Journal of Anaesthesia

Volumn 107, Issue 1, 2011, Pages 48-56

  Hopkins, P M ^a,b,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

calcium, excitation coupled calcium entry, store operated calcium entry; dihydropyridine receptor; inhalation anaesthetics, desflurane, halothane, isoflurane, sevoflurane; malignant hyperthermia; methylene blue; neuromuscular blocking drugs, succinylcholine; ondansetron; ryanodine receptor; RYR1; serotonin

Indexed keywords

AMRINONE; CALCIUM ION; CHLOROETHANE; CURARE; CYCLOPROPANE; DESFLURANE; ENFLURANE; ENOXIMONE; ETHER; HALOTHANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLURANE; METHOXYFLURANE; METHYLENE BLUE; MUSCLE PROTEIN; ONDANSETRON; PANCURONIUM; RYANODINE RECEPTOR 1; SEROTONIN 2A AGONIST; SEVOFLURANE; SUXAMETHONIUM; TETRACAINE; THIOPENTAL; TUBOCURARINE CHLORIDE;

CALCIUM TRANSPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; HUMAN; INHALATION ANESTHESIA; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SKELETAL MUSCLE;

EID: 79959433550     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aer132     Document Type: Review

References (78)

1. Ball C. Unravelling the mystery of malignant hyperthermia. Anaesth Intensive Care 2007; 3(Suppl. 1): 26-31 (Pubitemid 46938781)
2. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 1962; 34: 395-6
3. Bergman JA. Idiopathic malignant hyperthermia. Review and report of a case. Arch Ophthalmol 1975; 93: 232-4
4. Lips FJ, Newland M, Dutton G. Malignant hyperthermia triggered by cyclopropane during cesarean section. Anesthesiology 1982; 5: 144-6 (Pubitemid 12164879)
5. Hall LW, Trim CM, Wolf N. Further studies of porcine malignant hyperthermia. Br Med J 1972; 2: 145-8
6. McGrath CJ, Rempel WE, Jessen CR, Addis PB, Crimi AJ. Malignant hyperthermia-triggering liability of selected inhalant anesthetics in swine. Am J Vet Res 1981; 42: 604-7 (Pubitemid 11122350)
7. Caropreso PR, Gittleman MA, Reilly DJ, Patterson LT. Malignant hyperthermia associated with enflurane anesthesia. Arch Surg 1975; 110: 1491-3
8. Pan TH, Wollack AR, DeMarco JA. Malignant hyperthermia associated with enflurane anesthesia: a case report. Anesth Analg 1975; 54: 47-9
9. Joseph MM, Shah K, Viljoen JF. Malignant hyperthermia associated with isoflurane anesthesia. Anesth Analg 1982; 61: 711-2 (Pubitemid 12047172)
10. Jensen AG, Bach V, Werner MU, Nielsen HK, Jensen MH. A fatal case of malignant hyperthermia following isoflurane anaesthesia. Acta Anaesthesiol Scand 1986; 30: 293-4 (Pubitemid 16075942)
11. Otsuka H, Komura Y, Mayumi T, Yamamura T, Kemmotsu O, Mukaida K. Malignant hyperthermia during sevoflurane anesthesia in a child with central core disease. Anesthesiology 1991; 75: 699-701
12. Ochiai R, Toyoda Y, Nishio I, et al. Possible association of malignant hyperthermia with sevoflurane anesthesia. Anesth Analg 1992; 74: 616-8
13. Fu ES, Scharf JE, Mangar D, Miller WD. Malignant hyperthermia involving the administration of desflurane. Can J Anaesth 1996; 43: 687-90 (Pubitemid 26291332)
14. Michalek-Sauberer A, Fricker R, Gradwohl I, Gilly H. A case of suspected malignant hyperthermia during desflurane administration. Anesth Analg 1997; 85: 461-2 (Pubitemid 27349164)
15. Reed S, Strobel GE Jr. An in-vitro model of malignant hyperther-mia: differential effects of inhalation anesthetics on caffeine-induced muscle contractures. Anesthesiology 1978; 48: 254-9 (Pubitemid 8323465)
16. Britt BA, Endrenyi L, Frodis W, Scott E, Kalow W. Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle. Can Anaesth Soc J 1980; 27: 12-5 (Pubitemid 10141757)
17. Ellis FR, Halsall PJ, Hopkins PM. Is the 'K-type' caffeine-halothane responder susceptible to malignant hyperthermia? Br J Anaesth 1992; 69: 468-70
18. Carpenter D, Robinson RL, Quinnell RJ, et al. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009; 103: 538-48
19. Hoenemann CW, Halene-Holtgraeve TB, Booke M, et al. Delayed onset of malignant hyperthermia in desflurane anesthesia. Anesth Analg 2003; 96: 165-7 (Pubitemid 36042053)
20. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-9
21. Claxton BA, Cross MH, Hopkins PM. No response to trigger agents in a malignant hyperthermia-susceptible patient. Br J Anaesth 2002; 88: 870-3 (Pubitemid 34618967)
22. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498-507
23. Douglas MJ, McMorland GH. The anaesthetic management of the malignant hyperthermia susceptible parturient. Can Anaesth Soc J 1986; 33: 371-8 (Pubitemid 16070623)
24. Schonell LH, Sims C, Bulsara M. Preparing a new generation anaesthetic machine for patients susceptible to malignant hyperthermia. Anaesth Intensive Care 2003; 31: 58-62 (Pubitemid 36267321)
25. Petroz GC, Lerman J. Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia. Anesthesiology 2002; 96: 941-6 (Pubitemid 34266689)
26. Hoerauf K, Funk W, Harth M, Hobbhahn J. Occupational exposure to sevoflurane, halothane and nitrous oxide during paediatric anaesthesia. Waste gas exposure during paediatric anaesthesia. Anaesthesia 1997; 52: 215-9 (Pubitemid 27116737)
27. Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. Anesthesiology 2011; 114: 205-12
28. Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 2010; 105: 417-20
29. Reber A, Schumacher P, Urwyler A. Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment. Anaesthesia 1993; 48: 862-5 (Pubitemid 23295032)
30. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970; 17: 293-315
31. Ellis FR, Keaney NP, Harriman DGF, et al. Screening for malignant hyperpyrexia. Br Med J 1972; 3: 559-61
32. Harrison GG. Anaesthetic-induced malignant hyperpyrexia: a suggested method of treatment. Br Med J 1971; 3: 454-6
33. Nelson TE, Jones EW, Bedell DM. Porcine malignant hyperthermia: a study on the triggering effects of succinylcholine. Anesth Analg 1973; 52: 908-11
34. Iaizzo PA, Wedel DJ. Response to succinylcholine in porcine malignant hyperthermia. Anesth Analg 1994; 79: 143-51 (Pubitemid 24203448)
35. Sigg DC, Iaizzo PA. Malignant hyperthermia phenotype: hypotension induced by succinylcholine in susceptible swine. Anesthesiology 2000; 92: 1777-88 (Pubitemid 30412499)
36. Christian AS, Ellis FR, Halsall PJ. Is there a relationship between masseteric muscle spasm and malignant hyperpyrexia? Br J Anaesth 1989; 62: 540-4 (Pubitemid 19127177)
37. Ellis FR, Halsall PJ, Christian AS. Clinical presentation of suspected malignant hyperthermia during anaesthesia in 402 probands. Anaesthesia 1990; 45: 838-41 (Pubitemid 20340405)
38. Laurence AS, Vanner GK, Collins W, Hopkins PM. Serum and urinary myoglobin following an aborted malignant hyperthermia reaction. Anaesthesia 1996; 51: 958-61 (Pubitemid 26343534)
39. Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg 1993; 77: 297-304 (Pubitemid 23221428)
40. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9 (Pubitemid 24128939)
41. O'Flynn RP, Shutack JG, Rosenberg H, Fletcher JE. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. Anesthesiology 1994; 80: 1228-33 (Pubitemid 24182595)
42. Hopkins PM. Anaesthesia and the sex-linked dystrophies: between a rock and a hard place. Br J Anaesth 2010; 104: 397-400
43. Hopkins PM. Use of suxamethonium in children. Br J Anaesth 1995; 75: 675-7
44. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-8 (Pubitemid 36553493)
45. Antognini JF. Creatine kinase alterations after acute malignant hyperthermia episodes and common surgical procedures. Anesth Analg 1995; 81: 1039-42
46. Pollock AN, Langton EE, Couchman K, Stowell KM, Waddington M. Suspected malignant hyperthermia reactions in New Zealand. Anaesth Intensive Care 2002; 30: 453-61 (Pubitemid 34855061)
47. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-28 (Pubitemid 30417227)
48. Gerbershagen MU, Wappler F, Fiege M, et al. Effects of a 5HT(2) receptor agonist on anaesthetized pigs susceptible to malignant hyperthermia. Br J Anaesth 2003; 91: 281-4 (Pubitemid 36950205)
49. Fiege M, Wappler F, Weisshorn R, et al. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia- susceptible swine. Anesthesiology 2003; 98: 944-9 (Pubitemid 36373230)
50. Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Schulte am Esch J. Phosphodiesterase-III-inhibition with amri-none leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine. Eur J Anaesthesiol 2005; 22: 283-8 (Pubitemid 40731991)
51. Riess FC, Fiege M, Moshar S, et al. Rhabdomyolysis following car-diopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia. Anesthesiology 2001; 94: 355-7 (Pubitemid 32125928)
52. Krivosic-Horber R, Depret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004; 21: 572-4 (Pubitemid 38987993)
53. Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49: 237-8 (Pubitemid 36418283)
54. Guis S, Figarella-Branger D, Mattei JB, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006; 55: 551-7 (Pubitemid 44289873)
55. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with halothane, caffeine and ryanodine in patients with malignant hyperthermia and other neuromuscular disorders. Br J Anaesth 1993; 70: 397-401 (Pubitemid 23112490)
56. Sheu CC, Tsai JR, Hung J-Y. Possible malignant hyperthermia during spinal anaesthesia with tetracaine. Anaesthesia 2007; 62: 200-1 (Pubitemid 46099857)
57. Endo M. Calcium-induced calcium release in skeletal muscle. Physiol Rev 2009; 89: 1153-76
58. Ohnishi ST. Effects of halothane, caffeine, dantrolene and tetra-caine on the calcium permeability of skeletal sarcoplasmic reticu-lum of malignant hyperthermic pigs. Biochim Biophys Acta 1987; 897: 261-8 (Pubitemid 17038872)
59. Mathew S, Linhartova L, Raghuraman G. Hyperpyrexia and prolonged postoperative disorientation following methylene blue infusion during parathyroidectomy. Anaesthesia 2006; 61: 580-3 (Pubitemid 43740713)
60. Gilman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol 2011; 25: 429-36
61. Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondan-setron is associated with lethal outcome. Pediatrics 2010; 125: e1514-7
62. Muldoon S, Sambuughin N, Bayarsaikhan M, Dirksen R, Karan S. A novel ryanodine receptor (RYR1) variant in two children with fatal spontaneous MH like events. Anesthesiology 2008; 109: A648
63. Gronert GA, Milde JH. Variations in onset of porcine malignant hyperthermia. Anesth Analg 1981; 60: 499-503 (Pubitemid 11083148)
64. Suresh MS, Nelson TE. Malignant hyperthermia: is etomidate safe? Anesth Analg 1985; 64: 420-4 (Pubitemid 15076774)
65. Raff M, Harrison GG. The screening of propofol in MHS swine. Anesth Analg 1989; 68: 750-1 (Pubitemid 20043214)
66. Britt BA, Webb GE, LeDuc C. Malignant hyperthermia induced by curare. Can Anaesth Soc J 1974; 24: 371-5
67. Hall GM, Lucke JN, Lister D. Porcine malignant hyperthemia IV: neuromuscular blockade. Br J Anaesth 1976; 48: 1135-41
68. Buzello W, Williams CH, Chandra P, Watkins ML, Dozier SE. Vecur-onium and porcine malignant hyperthermia. Anesth Analg 1985; 64: 515-9
69. Young A, Clarke C, Downey C, et al. Use of non-depolarizing neu-romuscular blocking drugs and markers of severity of malignant hyperthermia reactions. Br J Anaesth 2010; 105: 709P
70. Robinson RL, Carpenter D, Shaw M-A, Halsall PJ, Hopkins PM. Mutations in ryr1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977-89 (Pubitemid 44454050)
71. Flewellen EH, Nelson TE. In vivo and in vitro responses to magnesium sulphate in porcine malignant hyperthermia. Can Anaesth Soc J 1980; 27: 363-9 (Pubitemid 10085238)
72. 2+ release in skeletal muscle from humans susceptible to malignant hyperthermia. J Physiol 2002; 544: 85-95 (Pubitemid 35153815)
73. 2+ release channels in malignant hyperthermia. Biophys J 1997; 73: 1913-24 (Pubitemid 27425722)
74. 2+ release from the sarcoplasmic reticulum in skeletal muscle from humans susceptible to malignant hyperthermia. Anesthesiology 2004; 101: 1339-46 (Pubitemid 39564990)
75. 2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia. Br J Anaesth 2006; 97: 320-8 (Pubitemid 44295667)
76. 2+ entry in malignant hyperthermia-susceptible human skeletal muscle. J Biol Chem 2010; 285: 25645-53
77. Yang T, Allen PD, Pessah IN, Lopez JR. Enhanced excitation-coupled calcium entry in myotubes is associated with expression of RyR1 malignant hyperthermia mutations. J Biol Chem 2007; 282: 37471-8
78. 2+ entry, release, and retrograde signaling to the DHPR. J Gen Physiol 2010; 135: 619-28